Melanotan II
MetabolicMetabolic-medicine specialists evaluate Melanotan II against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5) MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation.. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 0.25-0.5 mg daily during loading, then 1-2x weekly protocol provide the clinical evaluation framework.
Key Takeaways
Metabolic lens: Melanotan II is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. The metabolic medicine framework evaluates Melanotan II against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.
Visceral fat and the cardiometabolic axis
Melanotan II's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
AMPK and mitochondrial signalling
Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Melanotan II engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.
Insulin signalling and glycemic effect
Melanotan II's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
In the metabolic syndrome population, Melanotan II for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where Melanotan II is used for weight management, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
Melanotan II for mitochondrial biogenesis is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, Melanotan II for cardiometabolic risk produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 0.25-0.5 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.25-0.5 mg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 0.25-0.5 mg | Daily during loading, then 1-2x weekly |
| Maintenance phase | SubQ | 1.25-0.5 mg | Ongoing with periodic pauses |
Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- Melanotan II + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Melanotan II's mechanism in metabolic / endocrine protocols.
- Melanotan II + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Melanotan II's mechanism in metabolic / endocrine protocols.
- Melanotan II + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Melanotan II's mechanism in metabolic / endocrine protocols.
- Melanotan II + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Melanotan II's mechanism in metabolic / endocrine protocols.
Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.
Lens-specific safety considerations for metabolic / endocrine use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Melanotan II | Cyclic α-MSH analogue | ~30 min | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Is Melanotan II appropriate alongside metformin or other diabetes medications?
What metabolic labs should I track?
What weight loss can I expect?
Pancreatitis or thyroid risk?
What are the safety considerations for Melanotan II?
How does Melanotan II affect glycemic and metabolic markers?
Start a Melanotan II Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified Melanotan II and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 1024 Da
- Sequence length
- 7 aa
- Half-life
- ~30 min
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Mechanistic + off-label
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for Melanotan II
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised